Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Woman taking medication

Azithromycin and doxycycline are two commonly used antibiotics investigated as separate treatments in the trial. Both drugs are being used by some doctors in the hope of treating COVID-19 in the early stages of the illness.

After reviewing interim analyses of both the azithromycin and doxycycline arms of the PRINCIPLE trial, the independent Trial Steering Committee advised the trial investigators, who concluded that there is no beneficial effect in patients aged over 50 who are treated with either antibiotic at home in the early stages of COVID-19. This is because interim data analyses show that neither treatment reduces the time taken for people to first report that they feel recovered sufficiently to achieve meaningful clinical benefit. The PRINCIPLE trial did not look at the effects of these drugs in patients who were already admitted to hospital with COVID-19.

No further people are therefore being randomised to receive azithromycin or doxycycline in the PRINCIPLE trial.

Read the full story on the Nuffield Department of Primary Care Health Sciences website.

The story is also featured on the University of Oxford website.

Similar stories

Smoking increases the risks of 56 diseases in Chinese adults

Smoking increases the risks of 56 diseases and kills more than one million adults in China each year from 22 different causes, according to new research published in The Lancet Public Health.

Success for Oxford researchers in The Genetics Society 2023 Awards

Researchers from Department of Physiology, Anatomy and Genetics, Radcliffe Department of Medicine and Nuffield Department of Population Health have been recgonised in The Genetics Society 2023 awards.

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.

Young lives under pressure as global crises hits mental health and well-being – report

The well-being and mental health of young people in low - and middle - income countries have been dramatically affected by the series of crises hitting the world. As the international community continues to struggle with the impact of COVID-19, conflict and climate change, the latest report from the Young Lives project shows a long-running upward trend in young people’s well-being has been sharply reversed alongside widespread anxiety and depression. Young people are less confident about their futures for the first time in the 20-year study.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings